Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Women 18 years and older who have a BRCA1 or BRCA2 mutation and who:
Contact: Dr. Meghna S. Trivedi by phone: 212-305-1945 or by email
The purpose of this study is to evaluate the effects of denosumab on ovarian cancer risk markers among premenopausal women with a BRCA1 or BRCA2 mutation, who are scheduled to undergo risk-reducing surgery to remove their ovaries and fallopian tubes. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases.
This is a randomized, multinational, 2-arm pilot study to evaluate the effects of denosumab on markers in the gynecologic tissues and blood of premenopausal BRCA1 or BRCA2 mutation carriers. You will be randomly assigned (meaning by chance or like tossing a coin) to one of two groups. Neither you nor your doctor will decide which group you are in.
The study has two arms. This means that patients in the study are placed in one of two different groups.